Phase 2b double-blind ritlecitinib trial in chronic spontaneous urticaria

Phase 2, randomised, double-blind trial of ritlecitinib tosilate in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Pfizer. Primary endpoints: Change from baseline in Urticaria Activity Score 7 (UAS7) at Week 12 and Incidence of treatment emergent adverse events, serious adverse events, and adverse events leading to discontinuation up to Week 12. Started Mar 2026; status: recruiting.